基因组不稳定性与[¹⁷⁷Lu]Lu-PSMA-I&T放射配体治疗缓解相关:一项探索性、初步的液体活检分析
该探索性研究对17例接受[¹⁷⁷Lu]Lu-PSMA-I&T治疗的转移性去势抵抗性前列腺癌患者进行血浆cfDNA全基因组测序,分析拷贝数变异(CNV)负荷与循环肿瘤DNA(ctDNA)水平。结果示未缓解者的cfDNA CNV负荷(P=0.048)和ctDNA水平(P=0.036)均高于缓解者,两者可区分PSA缓解(AUC分别为0.792、0.806)和1年总生存(AUC分别为0.778、0.847)。
要点
- 未缓解者cfDNA CNV负荷高于缓解者(P=0.048)。
- 未缓解者ctDNA水平高于缓解者(P=0.036)。
- cfDNA CNV与ctDNA可区分PSA缓解及1年总生存。
核心结论
- 未缓解患者表现出更高水平的cfDNA基因组不稳定性和ctDNA水平。
- 作者认为需在靶向方法之外开展全基因组CNV分析,以获得机制性放射生物学见解及其作为PSMA RLT缓解生物标志物的价值。
研究设计与样本
- 探索性、初步的液体活检分析,采集17例接受[¹⁷⁷Lu]Lu-PSMA-I&T治疗患者的血浆样本进行cfDNA分析。
- cfDNA行全基因组测序以建立拷贝数变异谱和ctDNA水平,并在PSA缓解组与未缓解组、1年总生存组间进行比较。
主要发现
- 未缓解者cfDNA CNV负荷高于缓解者(P=0.048)。
- 未缓解者ctDNA水平高于缓解者(P=0.036)。
- cfDNA CNV负荷区分PSA缓解的AUC为0.792,ctDNA水平区分PSA缓解的AUC为0.806。
- cfDNA CNV负荷区分1年总生存的AUC为0.778,ctDNA水平区分1年总生存的AUC为0.847。
局限性
- 原文在结论中写明需进一步开展全基因组CNV分析研究,以获得机制性放射生物学见解及其作为PSMA RLT缓解生物标志物的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PSMA-targeted radioligand therapies (PSMA RLT) are an effective and safe option for metastatic castration-resistant prostate cancer, but responsive subtypes and their biomarkers are not fully defined. METHODS: Plasma samples for cell-free DNA (cfDNA) analysis were collected from 17 patients undergoing [¹⁷⁷Lu]Lu-PSMA-I&T. CfDNA underwent whole-genome sequencing to establish copy number variation (CNV) profiles and circulating-tumor DNA (ctDNA) levels and compared between prostate-specific antigen (PSA) response- and 1-year overall survival (1YOS) groups. RESULTS: Non-responders exhibited higher degrees of cfDNA CNV burden (P = 0.048) and higher ctDNA levels (P = 0.036) than responders. Both markers allowed for the differentiation of responses (AUC: 0.792, 0.806) and 1YOS (AUC: 0.778, 0.847). CONCLUSION: Unresponsive patients exhibited higher levels of cfDNA genomic instability and ctDNA levels, warranting genome-wide CNV profiling studies next to targeted approaches for mechanistic radiobiological insights and their value as response biomarkers for PSMA RLTs.
引用
- Kluge K, Haberl D, Haug A, et al. Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40261406. doi:10.1007/s00259-025-07280-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。